Phase 3 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to give yourself the study drug by injection, or have someone trained to help you if you have vision or physical limitations
- You have been diagnosed with type 2 diabetes, your HbA1c (a measure of average blood sugar) is between 6.5% and 10%, and you have been on a stable diabetes pill regimen for at least 3 months before the study starts (if you take any medication) — note that certain diabetes medications called DPP-4 inhibitors or GLP-1 drugs are not allowed
- Your Body Mass Index (BMI) — a measure of body weight relative to height — is 27.0 or above
- You have tried at least once in the past to lose weight through diet and/or exercise without lasting success
Who may not be able to join:
- You have type 1 diabetes, have ever had a dangerous blood sugar crisis called ketoacidosis, or have had a severe high blood sugar episode in the past 12 months
- You have had one or more serious low blood sugar episodes, or you do not feel warning signs when your blood sugar drops too low, within the past 6 months
- Your fasting blood sugar was very high (above 270 mg/dL) on two separate days during the screening period
- Your body weight has changed by more than 5 kg (about 11 pounds) in the 3 months before the study
- Your weight problems are caused by another hormonal condition (such as Cushing's syndrome) or a specific genetic condition linked to obesity (such as Prader-Willi syndrome)
- You have had weight-loss surgery in the past, or are planning to have it (minor cosmetic procedures done more than 1 year ago may be allowed — confirm with trial site)
- You have a known serious problem with how your stomach empties food, such as severe gastroparesis (confirm with trial site)
- Your blood pressure is poorly controlled at the time of screening
- You have had a heart attack, stroke, unstable chest pain, or been hospitalised for heart failure within the 3 months before the study
- You have used any GLP-1-based diabetes or weight-loss medication (such as semaglutide or tirzepatide) within the 6 months before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. Only)
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent (%) Change from Baseline in Body Weight at Week 72
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.